^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    7d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    10d
    Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Tanta University | Not yet recruiting --> Recruiting
    Enrollment open
    10d
    CAPTAIN: Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage (clinicaltrials.gov)
    P3, N=316, Not yet recruiting, Beijing Tiantan Hospital
    New P3 trial
    14d
    A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke (clinicaltrials.gov)
    P4, N=483, Completed, SK Chemicals Co., Ltd. | Recruiting --> Completed
    Trial completion
    15d
    Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Tanta University
    New P1/2 trial
    17d
    WEANLESS: Shorter Weaning From Invasive Ventilation With Levosimendan (clinicaltrials.gov)
    P4, N=250, Recruiting, Radboud University Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    27d
    Effects of Xuebijing combined with levosimendan on immune function and coagulation function in sepsis patients with myocardial injury. (PubMed, J Thromb Thrombolysis)
    Levels of NO, VEGF, PLT, Fib, CD4+, CD4+/CD8+ ratio, MAP and CVP were higher in the combination group than in the control group (all P < 0.05). The combination of XBJ and levosimendan improves coagulation function, regulates immune function, enhances vascular endothelial function and hemodynamics, reduces inflammation, and alleviates myocardial injury.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CRP (C-reactive protein)
    1m
    Safety and Efficacy of Levosimendan for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial (ChiCTR2500110769)
    P4, N=100, Not yet recruiting, the First Hospital of Jilin University.; the First Hospital of Jilin University.
    New P4 trial
    1m
    Phase I study on the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose administration in healthy subjects and multiple-dose administration in COPD patients of HRS-9821 inhalation powder aerosol (ChiCTR2500107601)
    P1, N=82, Not yet recruiting, West China Hospital of Sichuan University; Guangdong Hengrui Medicine Co., Ltd.
    New P1 trial
    1m
    A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Verona Pharma plc | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    Mulberry (Morus alba l.) leaf improves arachidonic acid metabolism disorder in chronic obstructive pulmonary disease. (PubMed, Phytomedicine)
    ARA metabolic dysregulation contributes to COPD pathogenesis, and (±)12-HETE, 15(S)-HETE, and (±)11-HETE may serve as potential biomarkers for COPD. MLWE exert therapeutic effects by modulating ARA metabolism, ameliorating oxidative stress, and suppressing inflammatory responses, offering a novel strategy for COPD prevention and treatment.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • LOX (Lysyl Oxidase) • IL1B (Interleukin 1, beta) • ALOX15 (Arachidonate 15-Lipoxygenase) • CAT (Catalase)
    2ms
    Prevention of Cisplatin-induced Nephrotoxicity (clinicaltrials.gov)
    P2/3, N=24, Not yet recruiting, Mahidol University | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin